“MAP is the only consultancy in the world to reduce time and cost in facilitating patient access, by offering integrated support from experts in patient and political engagement, pricing and reimbursement strategy, HTA submissions, HEOR, clinical writing, legal insights to prevent delays, all in addition to the breadth of our MAP Online content, which is validated by in-country experts. Our team has over 200 years of collective experience managing patient access challenges across international markets, and our success rate is over 95%.”
Christian Hill, CEO
Market Access strategy
Policy and public affairs
Market access legal advice
This enables us to provide our clients with a professional and integrated response to the challenges they face.
Our bespoke consultancy service provides structured product specific and organisational support. Our holistic approach generates simple and cost-effective solutions. The services range from strategy development to execution in the pre-launch, peri-launch and post-launch environments.
MAP offer product specific, one-to-one expert strategic advice on a consulting basis throughout the product lifecycle across the EU and other international markets. Our wealth of experience can help you develop a fully comprehensive strategy to seamlessly bring your product to market, while mitigating risks associated with price erosion due to international reference pricing or inefficient launch sequencing.
MAP offer strategic insight and a truly joined-up package in the UK and Ireland whilst leveraging our experience to support companies in other European and international markets.
Health economics and outcomes research (HEOR) information helps you to understand a product's value and its potential in real-world clinical practice. MAP are experts in evidence generation to support you with your HTA submission, having helped clients with over 200 HTA submissions.
Bringing new medicines to market is a long and complicated process with many different stakeholders involved. It is therefore crucial that companies are involved in clinical engagement that can help them understand different viewpoints for your product. Done well, it will help you develop a more comprehensive Market Access strategy.
In a shifting healthcare landscape with improved transparency, patients have become an increasingly integral stakeholder in the delivery of health services. Patient engagement can help the integration of innovative medicines into the health services and develop new opportunities.
But how and when should you engage and what trends and drivers are shaping patient involvement?
Strategic policy and public affairs activity can shape the environment for your company or product. It will address potential challenges or developments that may have an impact on patient access. MAP’s in-depth understanding of the policy and public affairs environment for the health sector and established relationships with stakeholders and decision-makers will help you ensure that opportunities are created and maximised through nuanced engagement with relevant stakeholders.
MAP BioPharma’s Policy and Public Affairs Code of Conduct sets out how we ensure an ethical approach to all Policy and Public Affairs activity that we undertake.
Copyright © 2020. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
+44 (0) 1480 832360
MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52